INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

About this update from Inmune Bio Inc.

[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ESFQnG17m_59Q1hSBmvAug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Company to Host Conference Call Today, August 7th, at 4:30pm ET","length":63,"tagName":"p"},{"type":"text","content":"BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended June 30, 2025 and provides a business update.","length":345,"tagName":"p"},{"type":"text","content":"Q2 2025 and Recent Corporate Highlights  ","length":44,"tagName":"p"},{"type":"text","content":"DN-TNF Platform Highlights (XPro™):","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Released top-line data from the MINDFuL phase 2 trial in 208 patients with MCI and early Alzheimer’s.","length":101,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The trial missed its primary cognitive endpoints in the 200 modified mITT patients enrolled, however;","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"XPro™ demonstrated a positive impact on the primary cognitive endpoint EMACC in a pre-defined subset of 100 patients (50%) with two or more biomarkers of inflammation, defined as the enriched population.","length":208,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":309,"olType":false}]},{"val":[{"type":"text","content":"Additional data from the MINDFuL trial was presented by a Key Opinion Leader, Dr. Sharon Cohen of the Toronto Memory Program, at the Alzheimer’s Association International Conference (AAIC) on July 29th. This data is summarized in the forest plot below.","length":252,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":662,"olType":false},{"type":"image","alt":"Data Summary","displaySize":"...

More updates from Inmune Bio Inc.